Author: Kerry Lutz's Financial Survival Network

In this fascinating episode, Kerry Lutz engages with Ben Lightburn, CEO of Filament Health, to unravel the complex world of psychedelics and their therapeutic potential. Ben provides an in-depth look at the mechanisms of psychedelics, focusing on the predominant theory of serotonin receptor agonists and their transformative impact on mental health. The discussion takes a critical turn as they explore the ethical dimensions of placebo-controlled studies in psychedelic research, acknowledging the potential for challenging experiences during therapy sessions. Kerry probes into the financial health and future of Filament Health, prompting Ben to shed light on the company’s drug development journey…